Trials / Completed
CompletedNCT00866528
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib | oral pazopanib once daily (Phase I starting dose 800 mg) |
| DRUG | paclitaxel | paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2). |
Timeline
- Start date
- 2009-07-09
- Primary completion
- 2012-10-25
- Completion
- 2012-10-25
- First posted
- 2009-03-20
- Last updated
- 2017-11-13
Locations
4 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00866528. Inclusion in this directory is not an endorsement.